Back to top
more

Enanta Pharmaceuticals (ENTA)

(Delayed Data from NSDQ)

$6.99 USD

6.99
101,796

-0.13 (-1.83%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $6.99 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Shire (SHPG) Q4 Earnings Beat, Immunology Franchise Strong

by Zacks Equity Research

Shire (SHPG) reported better-than-expected fourth-quarter earnings and also registered strong growth in immunology franchise and newly launched products.

    Zacks Equity Research

    AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda

    by Zacks Equity Research

    AVEO Oncology (AVEO) is due to receive $2 million from its partner EUSA Pharma as the latter has been granted positive NICE recommendation for Fotivda (tivozanib).

      Zacks Equity Research

      Will Conatus Liver Disease Candidate Drive Long-Term Growth?

      by Zacks Equity Research

      Conatus' (CNAT) efforts to develop lead candidate emricasan in absence of an approved product in the company's portfolio are a positive step toward driving growth.

        Zacks Equity Research

        Enanta Pharmaceuticals (ENTA) Looks Good: Stock Adds 9.6% in Session

        by Zacks Equity Research

        Enanta Pharmaceuticals, Inc. (ENTA) was a big mover last session, as the company saw its shares rise over 9% on the day.

          Zacks Equity Research

          Surging Earnings Estimates Signal Good News for Enanta Pharmaceuticals (ENTA)

          by Zacks Equity Research

          Enanta Pharmaceuticals (ENTA) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.

            Zacks Equity Research

            Will Conatus Key Candidate Emricasan Drive Long-Term Growth?

            by Zacks Equity Research

            Conatus's (CNAT) efforts to develop lead candidate emricasan in absence of an approved product in its portfolio are a positive step by the company to propel growth.

              Zacks Equity Research

              AbbVie's HCV Combo Drug Mavyret Clinches Approval in Canada

              by Zacks Equity Research

              AbbVie (ABBV) announces Mavyret's sanction in Canada for treatment of HCV across all major genotypes. This gain serves a big boost to the company's product portfolio.

                Zacks Equity Research

                Zacks.com featured highlights: Columbus McKinnon, The New York Times, Advanced Accelerator Applications, Enanta Pharmaceuticals and Caesars Entertainment

                by Zacks Equity Research

                Zacks.com featured highlights: Columbus McKinnon, The New York Times, Advanced Accelerator Applications, Enanta Pharmaceuticals and Caesars Entertainment

                  Zacks Equity Research

                  Buy These 5 Stocks on New Analyst Coverage

                  by Zacks Equity Research

                  Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.

                    Arpita Dutt headshot

                    4 Drug Stocks in Focus this World Hepatitis Day

                    by Arpita Dutt

                    Does the hepatitis C virus (HCV) market still hold potential for companies like Gilead (GILD)?

                      Zacks Equity Research

                      AbbVie's HCV Combo Drug Gets Positive CHMP Opinion in EU

                      by Zacks Equity Research

                      AbbVie Inc. (ABBV) announced that the CHMP of the EMA has recommended marketing approval of its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P).

                        Zacks Equity Research

                        AbbVie (ABBV) Presents Positive Data on HCV Combination Drug

                        by Zacks Equity Research

                        AbbVie Inc. (ABBV) announced that data from two phase III studies, EXPEDITION-1 and ENDURANCE-3, evaluating its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P) for all genotypes of Hepatitis C virus (HCV)

                          Zacks Equity Research

                          AbbVie (ABBV) HCV Regimen Gets Priority Review in Canada

                          by Zacks Equity Research

                          AbbVie Inc. (ABBV) announced that its New Drug Submission (NDS) for an investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) received priority review in Canada for treatment of HCV.

                            Zacks Equity Research

                            AbbVie's HCV Regimen Okayed for Accelerated Assessment

                            by Zacks Equity Research

                            AbbVie Inc. (ABBV) recently announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application for its investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P).